Navigation Links
Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure
Date:5/13/2008

pany believes that accumulation of A.G.E.s might prove to be a promising, novel target for the treatment of heart failure. A.G.E.s are proteins formed by oxidative or non-oxidative reactions. A.G.E.s cause the formation of collagen cross-links, which result in increased myocardial stiffness whereby the stiff ventricle fails to relax adequately between beats and allow blood to fill the chamber. As a result, blood backs up into the lungs and makes patients short of breath. More than 50% of patients with symptoms of heart failure have evidence of a stiff non-compliant ventricle (heart chamber) by echocardiogram.

About Synvista Therapeutics

Synvista Therapeutics is a biopharmaceutical company developing drugs to treat and prevent cardiovascular disease and nephropathy in people with diabetes. The Company believes it has identified several product candidates that represent novel approaches to some of the largest pharmaceutical markets. The Company's portfolio includes orally bioavailable, organoselenium mimics of glutathione peroxidase. These compounds metabolize lipid peroxides and have the potential to limit myocardial damage subsequent to a myocardial infarction. The Company is developing a clinical diagnostic test, based on cardiovascular risk assessment, using Haptoglobin characterization, to identify patients at high risk for cardiovascular complications of diabetes.

Synvista Therapeutics also is developing alagebrium, a proposed breaker of AGEs for the treatment of diastolic heart failure. This disease represents a rapidly growing market of unmet medical need, particularly common among diabetic patients. Alagebrium has demonstrated relevant clinical activity in two Phase 2 clinical trials in heart failure, as well as in animal models of heart failure and nephropathy, among others. Alagebrium has been tested in approximately 1,000 patients in multiple Phase 1 and Phase 2 clinical trials, allowing Synvista Therapeutics to assemble a sizeable hum
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Synvista Therapeutics to Present at Acumen BioFin Rodman & Renshaw 5th Annual Global Healthcare Conference
2. Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales
3. Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
4. Synvista Therapeutics to Present at the 10th Annual BIO CEO & Investor Conference
5. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
6. Synvista Therapeutics to be Featured on Wallst.net
7. Synvista Therapeutics to Present at the BIO InvestorForum 2007
8. TorreyPines Therapeutics to Host First Quarter 2008 Results Conference Call and Webcast
9. President and CEO of Velcura Therapeutics Inc. Named the 2008 Grant Thornton Leader and Innovator of the Year
10. NuVasive Signs Definitive Agreement to Acquire Osteocel Biologics Business from Osiris Therapeutics
11. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/15/2008).... 15 /- Quincy Bioscience (Madison, W...n.com ), a dietary supplement,consisting of the je...otential to improve memory in healthy human subjec...articipants that completed a 30-day open-label,stu...ntation with,apoaequorin, a well-known calcium-bin...
(Date:10/15/2008)...ance, October 15 /-, (EUR ... 08/07 EUR ... millions sales change millions ... 71 17 23.8 70 16 Other EU c... 25 21 Other markets 1.5 ...
(Date:10/15/2008)...lo., Oct. 15 /- Bolder BioTechnology,...1.6 million Phase II Continuing,Renewal Small Busi...ong-Acting Beta Interferon for Multiple Sclerosis"...rders and Stroke (NINDS) of The National,Institute...rd is contingent,upon the achievement of certain r...
(Date:10/15/2008)...moting its new PadLock Set Saver product at the Am...t Conference in Salt Lake City,UT, at The Salt Pa.... 15 /- Baxa Corporation is promoting...gnet Conference, October,15-17, in Salt Lake City...., PadLock provides a secure seal for the end of th...
Breaking Biology Technology:Jellyfish Protein Shows Potential to Help With Memory 2Jellyfish Protein Shows Potential to Help With Memory 3Stallergenes: Sales at end September 2008: + 17% - 2008 Sales Guidance Revised Upwards: + 14% 2Stallergenes: Sales at end September 2008: + 17% - 2008 Sales Guidance Revised Upwards: + 14% 3Bolder BioTechnology Receives $1.6 million NIH Grant to Continue Development of Multiple Sclerosis Drug 2Baxa Corporation Features PadLock(R) Set Saver at the ANCC National Magnet Conference(TM) 2
... Technology Network (WTN) just turned one! It is b...ee what we have accomplished in just 12 months of ...by Amazon and powered by Goggle) wistechnology.co... reach, and page views compared to other technolog...st. WTN is read beyond Wisconsin with 30% of its, ...
...over Spirit, which bounced to a near pinpoint land...Saturday (Jan. 3) after a seven-month flight, prom...Madison scientists say. , ,John Valley, a UW-Madis...ducted isotopic analyses of meteorites believed to...onsiderably to our knowledge of Mars and whether o...
...,Lets start with the good in Midwest biotech in 20...ormance of the publicly traded Midwest biotech com... Index, which evaluates the top 20 biotech stocks ...tellar performance of the Nasdaq and Amex Biotech ...lly ticked up even more in the last trading days o...
.... - GE Medical Systems and University Community H...ealth network based in Tampa, Florida have announc...dvanced heart hospitals. GE Medical Systems will...scular hospital, designed to deliver cardiovascula...hnology, when it opens in the spring of 2005. , ,...
Other Biology Technology:WTN's First Year 2The Good, Bad, Ugly of Midwest Biotech in 2003 2The Good, Bad, Ugly of Midwest Biotech in 2003 3GE Medical Enables Digital Heart Hospital 2GE Medical Enables Digital Heart Hospital 3
(Date:10/15/2008)..., Ulrike Gaul, professor of molecular biology at ... professor of theoretical physics at New York Univ...or the first Alexander von Humboldt professorships... (LMU) Mnchen nominated the two scientists for thi... by the Humboldt Foundation panel. This distinctio...
(Date:10/15/2008)..., Salk researcher Dr. Fred H. Gage, professor in ...eio Medical Science Prize for his discovery of the...lian brains. He will officially receive the award ...edicine in Japan on Nov. 21. , Dr. Gage,s labora...tem and unexpected plasticity and adaptability to ...
(Date:10/15/2008)..., Reston, VA (October 28, 2008) -- A study(1) pub...al, Toxicological Sciences, which is published b...cology, describes the kidney toxicity of melamine ...to characterize the toxicity of the compounds that...This research points to a possible link between th...
(Date:10/15/2008)..., As concerns about the effects of global warming...ecember issue of Physiological and Biochemical Zo...re of only two degrees Celsius could have a devast...kangaroos. , "Our study provides evidence that c...e range contractions, and the possible extinction ...
Breaking Biology News(10 mins):2 Alexander von Humboldt professorships go to LMU Munich 22 Alexander von Humboldt professorships go to LMU Munich 32 Alexander von Humboldt professorships go to LMU Munich 42 Alexander von Humboldt professorships go to LMU Munich 5Global warming threatens Australia's iconic kangaroos 2Study shows increased education on nanotech human enhancement increases public concerns 4070 1Study shows increased education on nanotech human enhancement increases public concerns 4070 2Assurant Health Names Jennifer Kopps Wagner Senior Vice President and General Counsel 24093 1Assurant Health Names Jennifer Kopps Wagner Senior Vice President and General Counsel 24093 2First Ever National Biovigilance Network in the U S Reaches 241 Million in Funding Prepares for Fall Pilot Launch 24088 1First Ever National Biovigilance Network in the U S Reaches 241 Million in Funding Prepares for Fall Pilot Launch 24088 2First Ever National Biovigilance Network in the U S Reaches 241 Million in Funding Prepares for Fall Pilot Launch 24088 3First Ever National Biovigilance Network in the U S Reaches 241 Million in Funding Prepares for Fall Pilot Launch 24088 4First Ever National Biovigilance Network in the U S Reaches 241 Million in Funding Prepares for Fall Pilot Launch 24088 5PAREXEL Promotes Dr Mark A Goldberg to Chief Operating Officer 6582 1PAREXEL Promotes Dr Mark A Goldberg to Chief Operating Officer 6582 2PAREXEL Promotes Dr Mark A Goldberg to Chief Operating Officer 6582 3PAREXEL Promotes Dr Mark A Goldberg to Chief Operating Officer 6582 4
...r all its promise, the prospect of using nanoparti...cts has raised concerns about possible harmful eff... University of Michigan are addressing those conce...icles damage cell membranes---enough to cause cell...revented. , "If you,re inventing these sorts of ma...
...ees in the world¹s most productive forests -- fore... tend to die young, according to a U.S. Geological...f the journal Ecology Letters. This discovery coul... to ongoing and future environmental changes. , "O...the world¹s most productive forests may be those l...
...ltiple sclerosis (MS) can be an unpredictable dise...acks healthy nerve cells and disrupts normal nerve...mptoms—including tingling, paralysis, pain, fatigu...y or in combination, sporadically or persistently....flare-ups are common in the majority of patients. ...
...number of articles explore the use of positron emi...onsurgical techniques that open the door to unders...issue of the Society of Nuclear Medicine,s Journal...nimal imaging "is the ability to carry out many st..." said SNM member Michael J. Welch, Ph.D., co-auth...
Other Biology News:Probing the promise and perils of nanoparticles 2Live fast, die young true for forests too 2Gene Signatures Predict Interferon Response For Multiple Sclerosis Patients 2Use of PET can reduce, may eliminate more strenuous drug development trials with animals 2Use of PET can reduce, may eliminate more strenuous drug development trials with animals 3Use of PET can reduce, may eliminate more strenuous drug development trials with animals 4
Rad51B
Goat polyclonal to Dysadherin ( Abpromise for all tested applications). entrezGeneID: 53827
Ku80 Antibody Shipping Temperature: HOT Storage Temperature: -20C
This antibody detects an ~25 kDa band, corresponding to the expected molecular mass of Rab3A, on immunoblots. The antibody specificity is confirmed in peptide inhibition immunoblotting studies.
Biology Products: